April 04, 2026 06:21 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
‘Not denied a ticket’: Annamalai explains absence from BJP’s Tamil Nadu candidate list | ‘Ghar-wapsi soon’: PoK wants to return to India, claims Imam organisation chief | Kerala polls shocker: Tharoor’s convoy stopped, security guard attacked mid-campaign | AAP drops Raghav Chadha from key parliamentary role, sparks buzz over internal rift | Amit Shah to camp in West Bengal for 15 days during Assembly polls; predicts Mamata’s defeat in state and Bhabanipur | 'BJP plotting President’s Rule, don’t fall in the trap': Mamata Banerjee on Malda unrest, urges peace | 'Most polarised state': CJI Kant raps Bengal govt over 9-hour hostage of judicial officers | Bengal SIR protest: Judge pleads for help amid mob attack after 9-hour hostage ordeal | Bengal SIR progress: 47 lakh of 60 lakh adjudicated cases disposed of, Supreme Court informed | Amit Shah to join Suvendu Adhikari on Bhabanipur nomination day; BJP plans mega roadshow

Human antibody discovery could save lives from fungal killer: Study

| @indiablooms | Dec 12, 2018, at 04:01 pm

London, Dec 12 (IBNS): A new way to diagnose, treat and protect against stealth fungal infections that claim more than 1.5 million lives per year worldwide has been moved a step closer, according to research published in Nature Communications.

Despite public health efforts, many people who get fungal infections in their blood streams die, even if they can be identified and treated with antifungal drugs. These therapies are often ineffective on their own and increasingly the infections are becoming resistant to treatment with some of the front line antifungal drugs.

The new technique, within the Medical Research Council Centre for Medical Mycology at the University of Aberdeen and funded by the Wellcome Trust and Medical Research Council, is the first to successfully use antibodies that are cloned from patients who have recovered from an infection caused by the fungus Candida.  In addition to causing thrush in more than one hundred million every year, this fungus is also the fourth leading cause of serious life-threatening bloodstream infections in developed countries. In laboratory experiments, the research team used these cloned antibodies to successfully protect animals from Candida bloodstream infections and demonstrate their potential in both treating and diagnosing Candida infections.

Dr Fiona Rudkin, who led the research and is currently heading up the creation of an Aberdeen-based spinout company to conduct the next phase of therapeutic development, said: “There is an urgent need to develop better ways for diagnosing and treating life-threatening fungal infections.  Human antibodies have revolutionised the way many cancers are treated and diagnosed.  This research marks a huge step towards using similar antibody-based approaches to tackle fungal infections.  These antibodies will now be developed as novel antifungal drugs through the creation of mycoBiologics – a new spin out company based in Aberdeen focused on improving the outcome of patients suffering from life-threatening fungal infections.”

Professor Neil Gow of the University of Exeter, who supervised the research while at Aberdeen, said: “Globally, fungal infections are under-recognised as a major killer. They’re hard to detect and for every day we fail to diagnose a serious fungal infection, the chances of survival diminishes. This research brings us a step closer to a day when we can use the antibodies that are generated by the human body to diagnose and treat fungal infections.”

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.